Brexit, Brexit Everywhere And Such A Lot To Think
Executive Summary
For medtech manufacturers working in the EU market, the biggest regulatory changes for a generation are on the cusp of coming into force – at last. Or does this spell double trouble for UK manufacturers, who are rightly nervous about how Brexit will alter their business?
You may also be interested in...
UK MHRA Presses For Leading Global Role Post-Brexit
The UK MHRA believes it has a valid and vital role to play on the global regulatory stage even after the UK leaves the EU.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.